Apogee Therapeutics, Inc. Common Stock (APGE NASDAQ) stock market data APIs
$92.8943
0.05(0.1%)
as of April 17, 2026
Try our APIs with
free plan!
Apogee Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Prev. Close
92.8943
Open
92.9443
High
95.7703
Low
91.7271
52 wk Range
32.36-95.315
Market Cap
6 878 M
Shares Outstanding
61 111 K
EPS
-1.03
Beta
1.025
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Apogee Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Apogee Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Apogee Therapeutics, Inc. Common Stock Fundamental Data
Apogee Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -284 176 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-10
- EPS/Forecast: -0.62
Get Apogee Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apogee Therapeutics, Inc. Common Stock News
New
Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data
Apogee Therapeutics recently completed a follow-on equity offering of approximately US$403,000,000, issuing 5,750,000 common shares at US$70.00 each after reporting positive 52-week Phase 2 APEX data ...
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee Therapeutics SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics ...
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors
Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics(NASDAQ:APGE), reported the sale of 20,000 shares of common stock in multiple open-market transactions on March 11, 2026, accord...
Apogee Therapeutics prices upsized $350M offering at $70 a share
Apogee Therapeutics (APGE [https://seekingalpha.com/symbol/APGE]) has announced the pricing [https://seekingalpha.com/pr/20450118-apogee-therapeutics-inc-announces-pricing-of-350-million-underwritten-...
Get Apogee Therapeutics, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
